BRAF Mutations Open Doors for N-Ethyl-N-Nitrosourea-Induced Gliomagenesis.
BRAF Mutations Open Doors for N-Ethyl-N-Nitrosourea-Induced Gliomagenesis.
复制标题
DOI：
10.1016/j.ajpath.2016.07.005
复制
发表时间：
2016-10
期刊：
影响因子：
--
通讯作者：
R. S. McNeill;David M. Irvin;C. Miller
中科院分区：
文献类型：
--
作者：
R. S. McNeill;David M. Irvin;C. Miller
在本期《美国病理学杂志》上，Wang等1通过DNA测序鉴定了N-乙基-N-亚硝基脲（ENU）诱导的大鼠胶质瘤中复发性Braf突变。他们的结果为BRAF突变型胶质瘤的新型靶向治疗的临床前开发提供了平台。精确肿瘤学有望通过根据肿瘤的分子特征对其进行分层并在分子定义的患者群体中使用合理设计的治疗方法来彻底改变癌症治疗。虽然肿瘤学领域正在向精准医学时代过渡，但基于组织类型、肿瘤病理学和患者人口统计学的传统诊断仍然是优质护理的关键。神经胶质瘤是人类最常见的原发性脑肿瘤，其一种自然病理学分类是基于其侵袭性，非弥漫性神经胶质瘤形成界限清楚的肿瘤，而弥漫性神经胶质瘤侵入正常脑。3在这两个广泛的诊断类别中，胶质瘤根据患者人口统计数据进一步细分为儿科和成人疾病，并根据其组织学外观进一步细分为特定的诊断实体。
In this issue of the American Journal of Pathology, Wang et al 1 identified recurrent Braf mutations in N-ethyl-N-nitrosourea (ENU)–induced rat gliomas by DNA sequencing. Their results provide a platform for preclinical development of novel targeted therapies for BRAF-mutant gliomas. Precision oncology promises to revolutionize cancer therapy by stratifying tumors on the basis of their molecular characteristics and using rationally designed treatments in molecularly defined patient populations. 2 Although the field of oncology is transitioning into the precision medicine era, conventional diagnostics, based on tissue type, tumor pathology, and patient demographics, remain essential to quality care. One natural pathological division for gliomas, the most common primary brain tumors in humans, is based on their invasion, with nondiffuse gliomas forming well-circumscribed tumors and diffuse gliomas invading the normal brain. 3 Within these two broad diagnostic categories, gliomas are further subdivided on the basis of patient demographics into pediatric and adult diseases and further into specific diagnostic entities based on their histological appearance.